Pfizer launches production in Russia

12 January 2017

US pharma giant Pfizer (NYSE: PFE) has launched the production of three of its drugs in Russia, at the St Petersburg facilities of Polysan, one of the country’s leading drugmakers, reports The Pharma Letter’s local correspondent.

The new line will include a drug for the correcting dyslipidemia (cholesterol), tablets for the treatment of rheumatoid arthritis and an antibacterial agent, the names of the drugs are currently not disclosed.

Production takes place as part of the contract that was signed between Pfizer and Polysan on January, 25 2016.Financial and technical details of the project are not disclosed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK